MedWatch survey approved
This article was originally published in The Tan Sheet
The Office of Management & Budget has approved FDA's online MedWatch customer satisfaction survey of health care trade groups and specialty organizations that voluntarily participate in the agency's MedWatch Partners program, the agency announces Aug. 16. FDA solicited comments in May on its proposed survey "about the utility of the FDA MedWatch safety alerts and monthly safety labeling changes" posted on the MedWatch website and sent to partner organizations for distribution to organization members, according to a Federal Register notice...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”